Clinical Trials Browser

Lung Neoplasms

NCT00769483 2020-09-03

MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer

Phase 1/2 Completed

81 enrolled 19 charts

Gastrointestinal

Pancreatic Neoplasms

NCT01609231 2020-05-04

MK-0646-025

Phase 2 Terminated

11 enrolled 8 charts

Gastrointestinal

Rectal Neoplasms

NCT01605396 2019-03-25

MK-8669-064

Phase 2 Completed

80 enrolled 13 charts

Breast

Breast Neoplasms

NCT00635778 2018-10-09

MK-0646-002

Phase 1 Completed

50 enrolled 32 charts

Other solid neoplasm

Advanced Solid Tumors

NCT01243762 2018-08-16

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Phase 1 Terminated

47 enrolled 12 charts

GastrointestinalGynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT00759785 2018-08-15

MK-0646-013

Phase 1 Completed

48 enrolled 10 charts

Breast

Breast Neoplasms

NCT00925015 2018-08-15

Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016)

Phase 1 Completed

20 enrolled 30 charts

Gastrointestinal

Colorectal Neoplasms

NCT00614393 2018-08-08

Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)

Phase 2 Completed

558 enrolled 17 charts

Gastrointestinal

Colorectal Neoplasms

NCT00694356 2018-08-08

Study of Dalotuzumab (MK-0646) in Adults With Solid Tumors (MK-0646-009)

Phase 1 Completed

15 enrolled 13 charts

Tumor-Agnostic

Neoplasms

NCT00701103 2018-08-08

Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)

Phase 1 Completed

80 enrolled 23 charts

Plasma cell

Multiple Myeloma

NCT00951444 2016-07-06

Gemcitabine Hydrochloride and Carboplatin With or Without MK-0646 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01431547 2016-06-17

Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)

Phase 1 Completed

21 enrolled

Other solid neoplasm

Solid Tumors

NCT00729742 2016-04-04

Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)

Phase 1 Completed

49 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00610129 2015-11-20

Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)

Phase 2 Completed

25 enrolled 6 charts

EndocrineNET

Neuroendocrine Tumors

NCT00730379 2015-02-10

A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004)

Phase 1 Completed

87 enrolled

Tumor-Agnostic

Neoplasms

NCT00903006 2015-02-02

Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer

Phase 1/2 Terminated

11 enrolled 6 charts

Breast

Breast Neoplasms

NCT01220570 2015-01-21

The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)

Phase 1 Completed

63 enrolled

Breast

Breast Neoplasms

NCT00799240 2014-11-07

IMPACT

Phase 2 Completed

27 enrolled

Thoracic

Insulin-Like Growth Factor I, Resistance To, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pleural Effusion

NCT01175291 2011-12-05

FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Colorectal Neoplasms

Clinical Trials

MK-0646, Etoposide, and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer

MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer

MK-0646-025

MK-8669-064

MK-0646-002

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

MK-0646-013

Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016)

Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)

Study of Dalotuzumab (MK-0646) in Adults With Solid Tumors (MK-0646-009)

Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)

Gemcitabine Hydrochloride and Carboplatin With or Without MK-0646 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)

Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)

Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)

A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004)

Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer

The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)

IMPACT

FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer